BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.69M | -12.55M | -30.91M | -19.19M | -7.25M |
| Total Depreciation and Amortization | 58.00K | 74.00K | 75.00K | 75.00K | 76.00K |
| Total Amortization of Deferred Charges | 502.00K | 469.00K | 440.00K | 393.00K | 350.00K |
| Total Other Non-Cash Items | -1.03M | -7.04M | 13.21M | 3.74M | -3.63M |
| Change in Net Operating Assets | 1.35M | 4.83M | -1.60M | 2.41M | -1.58M |
| Cash from Operations | -11.81M | -14.21M | -18.79M | -12.58M | -12.04M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.11M | -- | -- | -- | -- |
| Issuance of Common Stock | 8.50M | 5.76M | 38.23M | 140.00K | 14.01M |
| Repurchase of Common Stock | -- | 0.00 | -16.00K | 0.00 | -1.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -158.00K | -115.00K | -686.00K | -3.00K | -803.00K |
| Cash from Financing | 232.00K | 5.65M | 37.53M | 137.00K | 13.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.58M | -8.56M | 18.75M | -12.44M | 1.16M |